Todas las investigaciones
ReclutamientoExploratorio terapéutico (Fase II)Intervencionista

CAT-Trial: CGRP monoclonal Antibody for Treatment of painful diabetic neuropathy: a double-blind, multicenter, placebo-controlled, international phase II clinical trial

Many people with diabetes develop nerve damage, known as diabetic neuropathy, which can cause severe burning, shooting, or stabbing pain in the feet and hands. Current treatments do not always bring enough relief. The CAT-Trial is looking at a medicine called eptinezumab (also known as Vyepti). This medicine blocks a body chemical called CGRP, which is involved in sending pain signals to the brain. In this study, adult volunteers will receive either the study medicine or a harmless saltwater drip (placebo). Researchers will follow participants for 24 weeks to see if those receiving eptinezumab experience a meaningful drop in their daily pain scores compared to those on the placebo. Taking part helps scientists understand whether this treatment could offer a new option for managing chronic diabetic nerve pain in the future.

De un vistazo

Estado
Reclutamiento
Fase
Exploratorio terapéutico (Fase II)
Patrocinador
Aarhus University Hospital
Objetivo de inscripción
95
Inicio
27 de febrero de 2023

¿De qué trata este estudio?

Diabetes can sometimes damage the tiny blood vessels that supply our nerves, especially in the feet, legs, and hands. Over time, this damage can lead to a condition called painful diabetic neuropathy. People living with this condition often experience burning, tingling, aching, or shooting pains. These symptoms can make walking uncomfortable, disturb sleep, and have a major impact on quality of life. Everyday painkillers often fail to ease nerve pain, and other treatments do not work for everyone.

The CAT-Trial is an international research study exploring whether a medicine called eptinezumab can help. Eptinezumab is an antibody medicine that targets a specific protein in the body known as CGRP. CGRP acts like a messenger that carries pain signals along the nerves. By blocking this protein, researchers hope the medicine can calm overactive pain pathways and provide lasting relief.

In this trial, half the participants will receive eptinezumab through an intravenous drip, while the other half will receive a dummy drip containing sterile saltwater (a placebo). Neither the participants nor their study doctors will know which treatment is given. Over 24 weeks, researchers will compare pain scores between both groups. If successful, this trial could lead to new ways of helping people manage persistent diabetic nerve pain.

Puntos clave

  • The trial tests an antibody medicine called eptinezumab for nerve pain caused by diabetes.
  • The treatment is given as an intravenous drip into a vein in your arm.
  • Participants are followed for 24 weeks to track changes in their pain levels.
  • Half of the volunteers will receive the study medicine, and half will receive a dummy saltwater drip.
  • Taking part is voluntary, and you can stop at any time without losing your regular NHS care.

¿Quién puede ser elegible?

This trial is open to adults aged 18 and over who have been diagnosed with diabetes and are experiencing persistent nerve pain (painful diabetic neuropathy). Both men and women can join.

To be considered, your nerve pain must be ongoing and affecting your day-to-day life. Before you can join, the study team will carry out a thorough health check to make sure the trial is safe for you. They will look at your general health, your current diabetes control, and any other medications you take.

People with certain other medical conditions or those taking specific medicines that might interfere with the study may not be able to participate. The study doctor will go through all the detailed criteria with you to confirm if the trial is a suitable match.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. I am aged 18 or older.
  2. I have been diagnosed with diabetes.
  3. I have ongoing nerve pain (such as burning, shooting, or tingling pain) in my feet, legs, or hands.
  4. I am willing to receive a treatment through a drip in a hospital or clinic.
  5. I can attend regular clinic appointments and record my daily pain scores over 24 weeks.
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you take part, your participation will last around 25 weeks in total. It begins with a one-week baseline period where you will track your usual pain levels each day using a simple 0 to 10 scale.

Next, you will attend a clinic visit to receive the study treatment. The medicine (or the saltwater placebo) is given slowly into a vein in your arm through a drip. You will be monitored closely by nurses during and after the infusion.

Over the next 24 weeks, you will attend regular follow-up visits, including key check-ups at weeks 12 and 24. At these appointments, the medical team will check your overall health, monitor any side effects, and ask you to complete short questionnaires about your pain levels and daily wellbeing. You will also continue recording your pain levels at home.

Riesgos y beneficios potenciales

Taking part may help reduce your diabetic nerve pain, although there is no guarantee you will personally benefit, particularly if you receive the placebo drip. However, the information gathered will help improve future care for people with this condition. As with any medicine, there are potential side effects. These can include mild reactions around the infusion site, temporary allergic reactions, tiredness, or headaches. The medical team will watch over you carefully at every visit. Joining the study is completely voluntary, and you are free to leave at any time without it affecting your regular NHS care.

Ubicaciones (1)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    Dinamarca

Preguntas comunes

What is eptinezumab?

Eptinezumab (brand name Vyepti) is a medicine designed to block CGRP, a chemical messenger in the body that helps transmit pain signals.

¿Qué es un placebo?

A placebo is a dummy treatment that looks just like the real medicine but contains no active ingredients, such as a simple saltwater drip.

Will I have to pay to take part?

No, you do not need to pay. The study medicine, tests, and clinic appointments are provided free of charge, and travel expenses are often covered.

Can I keep taking my usual diabetes medicines?

In most cases, you will continue your regular diabetes care. The study doctor will check all your prescriptions to ensure they are safe to use alongside the study.

Can I leave the study early if I change my mind?

Yes. You can withdraw from the trial at any point, for any reason, and your normal healthcare will continue as usual.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "CAT-Trial: CGRP monoclonal Antibody for Treatment of painful…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.